TOPIC

/ company

Wuxi Biologics

Wuxi Biologics is a pharmaceutical research and services company based in Wuxi, Jiangsu province. It counts 16 of the world's top 20 drug makers as customers and 28 of China's 50 largest medicine producers. The company supplied ingredients for AstraZeneca's Covid-19 vaccine. It is one of six businesses founded by its chairman Ge Li, along with Wuxi Apptec.

Chairman / President

Li Ge

CEO / Managing Director

Chen Zhisheng

CFO / Finance Director

Tu Ming

Industry

Biopharmaceutical

Website

wuxibiologics.com.cn

Headquarters address

No. 108 Mashan Meiliang Road, Binhu Distroct, Wuxi City, Jiangsu Province, China

Stock Code

SEHK:2269

Year founded

2010

The Trump administration’s new 100 per cent tariff on any branded or patented pharmaceutical product takes effect on October 1. Photo: Shutterstock

Biomedicine: Geopolitics

Trump’s tariffs on imported drugs ‘not a big concern’ for China’s pharma firms

Chinese drug makers have ‘minimal sales exposure to the US’, Jefferies analysts say.

26 Sep 2025 - 7:00PM

Wuxi Biologics

Trump’s tariffs on imported drugs ‘not a big concern’ for China’s pharma firms

Chinese drug makers have ‘minimal sales exposure to the US’, Jefferies analysts say.

Hong Kong stocks cap weekly decline on valuation, tariff jitters

Chinese biotechs get a shot in the arm from policy support, licensing deals

Chinese biotech firm MGI’s DNA sequencers gaining in the market, BGI CEO says

MGI’s latest product, the DNBSEQ-T7+, can sequence 144 human genomes a day, or one every 10 minutes.

Hong Kong stocks slip from 4-year high amid fears of US sanctions on drug makers

The Trump administration has been discussing severe restrictions on medicines from China, according to The New York Times.

Alibaba surge leads Hong Kong stocks to biggest gain in 2 weeks

Hong Kong stocks are undervalued, and a ‘liquidity friendly environment’ is set to propel them higher, analyst says.

Hong Kong stocks rebound on US-China trade talk optimism

Hang Seng Index recovers from an intraday loss of as much as 0.9 per cent, snapping a four-day losing streak.

Hong Kong stocks sustain 3-year-high level on trade optimism

A US deal with Japan and scheduled talks with China reduce concerns about damage to the global economy from trade conflicts.

Hong Kong stocks cap weekly gain on earnings optimism

Wuxi AppTec jumps after it says its first-half profit likely more than doubled from a year earlier.

Hong Kong stocks gyrate amid Iran conflict after US strike, Hormuz threat

Oil futures surge after US President Donald Trump says attacks ‘obliterated’ targets and Iran threatens to close key oil shipping route.

Hong Kong stocks rise on China policy hopes after soft economic data

China’s industrial output and fixed-asset investment fell short in May, and the downturn in the property market deepened.

Hong Kong stocks erase gains amid ongoing US-China trade talks

Investors appear to look more cautiously at ongoing US-China trade talks in London.

Hong Kong stocks jump as US blocks Trump’s tariffs in win for global trade

Hang Seng Index approached a two-month high on bets global trade relations and market sentiment will improve.

Hong Kong stocks gain on earnings boost as Meituan beats market consensus

Gains limited by losses in leading carmakers amid lingering concerns about a prolonged price war.

Big Chinese pharma can beat Trump’s policies with cost efficiencies: analysts

Trump seeks to slash domestic drug prices, bring back pharmaceutical manufacturing to the US and slap tariffs on imports.

Biomedicine | China’s biomedical sector braces for headwinds

The coast isn’t entirely clear for the world’s second-largest biomedical sector, which faces possible tariff increases and US import curbs.

China’s WuXi Biologics to sell Irish vaccine facility to Merck as US curbs loom

US passed Biosecure Act which would ban federal contracts with targeted firms and their business partners. Legislation explicitly names WuXi.

WuXi AppTec, WuXi Biologics surge on slimmer chances of Biosecure Act’s passage

The bill’s absence from the proposed amendments to the US National Defence Authorisation Act comes as a reprieve for the two biotech firms.

Shanghai to back local biopharma firms’ overseas push, regulatory compliance

The initiative aims to generate about US$7 billion from medical product exports by 2027.

WuXi AppTec, WuXi Biologics rise in Hong Kong as some operations go up for sale

The gains were made on the back of a report that said the two firms plan to sell certain overseas operations amid heightened US scrutiny.

Senior US official lauds China cooperation on tech-transfer controls

‘End-use checks’ have improved since the pandemic, but pending congressional legislation is keeping mainland firms in limbo.

‘China week’ at US House puts biotech firms, Hong Kong offices in cross hairs

Most of the scheduled 28 items have bipartisan support and follow efforts to tackle national and economic security threats posed by Beijing.

Hong Kong stocks surrender rally as WuXi Bio slumps 21% while Tencent, Li Auto gain

Stocks declined, capping another week of losses, after WuXi Biologics suffered another major plunge. Market surrendered an earlier rally fuelled by favourable Beijing policy and robust EV deliveries in January.

Hong Kong stocks rebound as WuXi Bio, Sands get support to stem market rout

Stocks rebound from a 13-month low, snapping a three-day slump. Some companies are quickly pushing for buy-backs to help stem losses and shore up market confidence.

Hong Kong IPO: WuXi Biologics unit eyes up to US$520 million in biotech push

WuXi XDC, a 60 per cent-owned unit of WuXi Biologics, could raise as much as US$520 million, including excess share allotment, based on the top end of its IPO price range.

China’s Wuxi Biologics to spin off international unit in Hong Kong IPO

Capital raised from the IPO of Wuxi XDC will go towards building new manufacturing facilities in Singapore, expanding production capacity in China, strategic investments and acquisitions, according to an exchange filing.

Most Hong Kong stocks rise as Beijing raises stimulus policy hopes

Most stocks on the Hang Seng Index rose on the prospect that Beijing will double down on policy measures to boost economic growth.

WuXi Biologics suspends trading after US list sparks record 32 per cent slump

WuXi Biologics sank by as much as 32 per cent, its steepest on record, before trading was suspended for an announcement. Some US$14.7 billion of market value in two related companies was erased in the sell-off.